Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia.
John E LevineStephan A GruppMichael A PulsipherAndrew C DietzSusana RivesG Douglas MyersKeith J AugustMichael R VernerisJochen BuechnerTheodore W LaetschHenrique BittencourtAndre BaruchelMichael W BoyerBarbara De MoerlooseMuna QayedStella M DaviesChristine L PhillipsTimothy A DriscollPeter BaderKrysta SchlisPatricia A WoodRajen ModyLan YiMimi LeungLamis K EldjerouCarl H JuneShannon L MaudePublished in: Journal for immunotherapy of cancer (2022)
This pooled analysis provides a detailed safety profile for tisagenlecleucel during the course of clinical trials, and AE management guidance, with a longer follow-up duration compared with previous reports.